Form 4 for BSX Boston Scientific
Accepted 2021-07-06 00:00:00 ET · period of report 2021-07-01 · accession 0001225208-21-010279 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-06 | 2021-07-01 | BSX | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | M - OptEx | $0.00 | +855 | 18.7K | +5% | $0 |
| D | 2021-07-06 | 2021-07-01 | BSX | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | F - Tax | $43.36 | -251 | 18.4K | -1% | -$10.9K |
| D | 2021-07-06 | 2021-07-01 | BSX | Scanlon Meghan | SVP, Pres, Urology Pelvic Health | M - OptEx | $0.00 | -855 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-01 | M | A | 855 | $0.00 | 18,685 | D | — | — | (F1) Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| 2 | Common | Common Stock | 2021-07-01 | F | D | 251 | $43.36 | 18,434 | D | — | — | |
| 3 | Derivative | Deferred Stock Units | 2021-07-01 | M | D | 855 | $0.00 | 0 | D | — · — to 2021-07-01 | 855 Common Stock | (F1) Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. (F2) Shares of common stock will be issued to the reporting person in five equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant. |